EUROPEAN MULTIDISCIPLINARY ON UROLOGICAL CANCERS..

15th European Multidisciplinary Congress on Urological Cancers (EMUC23)

 

02-05 November 2023 Marseille
Close
N. Poster
Poster title
Applicant name
Status
  P-001 Programmed death-ligand (PD-L1) immunoexpression and clinical outcomes in Penile Squamous Cell Carcinoma Ines Peyroteo Received Received
  O-001 MRI in penile cancer: Correlating examination and histopathology with imaging Mayank Gupta Received Received
  P-2 Saving More Than Just Skin: A Study of Penile Sparing Approaches in Cancer Treatment George Shaker Received Received
  P-005 The accuracy and intra- and interobserver variability of PSMA PET/CT for the local staging of primary prostate cancer Maarten Donswijk Received Received
  O-008 Intense surveillance for patients treated with radical prostatectomy and adverse pathologic features: early results from easy-1 (early salvage radiotherapy-1) protocol Martina Monti Received Received
  P-009 The probability of metastases within different Prostate-Specific Antigen (PSA) ranges using Prostate-Specific Membrane Antigen (PSMA) positron emission tomography in patients with newly diagnosed prostate cancer Wietske Luining Received Received
  O-010 The 3 year follow-up of the CRIMI study Marinka Remmelink Received Received
  O-011 Post-chemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer at a national referral center Panagiotis Vlachostergios Received Received
  O-12 Tumor Response by Baseline Metastases in Patients (Pts) With Renal Cell Carcinoma (RCC) Treated with Lenvatinib (L) Plus Pembrolizumab (P) vs Sunitinib (S): Post Hoc Analysis of the CLEAR Trial Laura Hendrickson Received Received
  P-012 Telomere biology as a prognostic factor in radical prostatectomy Juan Manuel Rubio Galisteo Received Received
  P-017 MRI/US fusion, transperineal prostate biopsy utilising electro-magnetic Vector needle tracking, under local anesthesia Marta De Santis Received Received
  P-021 The value of PSMA-PET in Addition to mpMRI and Systematic Biopsies to Select Patients for Hemi-ablative Focal Therapy in Prostate Cancer Matthijs Scheltema Received Received
  P-024 A randomized Phase 3 trial of Metformin in patients initiating androgen deprivation therapy as PRevention and Intervention of MEtabolic syndrome: The PRIME Study Nawaid Usmani Received Received
  P-032 Stereotactic prostate radiotherapy with or without androgen deprivation therapy: A phase III, multi-institutional randomized-controlled trial. The SPA trial Vittorio Morelli Received Received
  P-035 Validation of diagnostic nomograms based on mass spectrometry-based urinary biomarkers to distinguish clinically significant prostate cancer: complementing MRI pathway Ana Cristina Morillo Tejedor Received Received
  P-038 Local anaesthesia transperineal (LATP) biopsy of the prostate: a new era for prostate cancer diagnosis? Paul Lim Received Received
  P-039 Using PSMA PET to Guide Prostate Biopsies and Stage Men at High-Risk of Prostate Cancer Yves Bodar Received Received
  P-046 Salvage cryotherapy for prostate cancer Duarte Brito Received Received
  P-049 10-year experience of whole gland cryoablation: analysis of biochemical recurrence Alejandro Reviriego Barrús Received Received
  P-054 Toxicity results of a multicentre randomized phase 3, non-inferiority trial on moderate hypofractionated radiotherapy. Valerie Fonteyne Received Received
  P-060 Minimizing neurovascular bundle dose while maintaining target coverage in prostate radiotherapy Victor Brand Received Received
  P-064 Real-World Treatment and Outcomes in Localized Prostate Cancer Jose M. Calderon Received Received
  P-065 PSMA PET/CT in Biochemically Recurrent Prostate Cancer: multicenter external validation of a risk prediction nomogram Laura Chamorro Castillo Received Received
  P-068 Serum levels of vitamin E (Vit E) in patients with proctitis after radical radiotherapy for localized prostate cancer Geovana Marques Guimaraes Received Received
  P-069 PSA persistence after prostatectomy prognosis and the effect of adjuvant radiotherapy Axel Möller Received Received
  P-071 The association between patient- and disease characteristics, and the risk of disease progression in patients with prostate cancer on active surveillance Matthijs Duijn Received Received
  P-077 Baseline health-related quality of life as a prognostic indicator for survival in men with intermediate risk prostate cancer following radical prostatectomy Thilo Westhofen Received Received
  P-081 Real World Utilisation of Androgen Deprivation Therapy Among Urology Practices: Characterising Initiation and Transition to Relugolix for Patients with Prostate Cancer (The REAL ADT Transitions Study) Thierry Schulmann Received Received
  P-083 Post-metastasis survival in high-risk localised and locally advanced prostate cancer patients undergoing primary treatment in the United States: A retrospective study Erin OBrien Received Received
  P-085 The optimal timing of ARAT administration against nmCRPC Kazuhiro Matsumoto Received Received
  P-087 Acute toxicity results from a multicenter randomized phase 3 trial comparing external beam radiotherapy alone with external beam radiotherapy combined with brachytherapy in intermediate/high risk prostate cancer patients Miranda Christianen Received Received
  P-088 Salvage radiotherapy after prostatectomy; trends and variation in Dutch clinical practice Floor Staal Received Received
  P-093 Mutational profile of hormone-sensitive and castration-resistant metastatic prostate cancer Clara Velasco Balanza Received Received
  P-096 Real-world data analysis of clinical characteristics in metastatic hormone-sensitive prostate cancer: Are patients from RCTs the same from real life? Data from the European network of excellence for big data in prostate cancer (PIONEER). Juan Gomez Rivas Received Received
  P-098 Real-world characterization of disease management and progression in metastatic and nonmetastatic castrate-resistant prostate cancer patients in Portugal: CaPA study Catarina Leitao Received Received
  P-100 Apalutamide in Metastatic Prostate Cancer real life experience Duarte Brito Received Received
  P-101 Treatment (tx) patterns and outcomes in the real world (rw) among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in Europe Melissa Kirker Received Received
  P-102 Matching-Adjusted Indirect Comparisons (MAICs) of Talazoparib versus Olaparib and Niraparib for First-line (1L) Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Melissa Kirker Received Received
  P-104 Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: Freedom from biochemical, radiological progression free survival and freedom from following treatment approaches within a randomized phase II trial (ARTO NCT03449719) Giulio Francolini Received Received
  P-105 Is achieving undetectable PSA (uPSA) a prognostic factor for improved overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving intensified treatments? Jose M. Calderon Received Received
  P-106 The conundrum of treating metastatic hormone sensitive prostate cancer Tessa van Elst Received Received
  P-107 A network meta-analysis on the safety of systemic treatments in metastatic hormone-sensitive prostate cancer patients Irene Luccarini Received Received
  P-108 Expert consensus recommendations for managing adverse events in patients with metastatic prostate cancer treated with poly(ADP-ribose) polymerase inhibitor (PARPi) novel hormonal therapy (NHT) combination therapy Hannah Dalglish Received Received
  P-109 An evaluation of service diversification in response to increasing therapeutic indications for 2nd generation hormone therapy in prostate cancer Alicia Hague Received Received
  P-111 New or worsening type 2 diabetes mellitus (T2DM) in men treated with enzalutamide (ENZ) or abiraterone acetate (AA) for metastatic castration-resistant prostate cancer (mCRPC): EVADE study Anna George Received Received
  P-112 Analysis of prostate-specific antigen (PSA) kinetics in the third month of treatment with apalutamide in metastatic castration-sensitive prostate cancer (mCSPC) Juan Luis Sanz Miguelañez Received Received
  P-114 The multicenter and randomized PROSFIT trial: Smart wearables to evaluate the impact of lifestyle changes in patients with metastatic hormone sensitive prostate cancer (mHSPC) Teresa Alonso Gordoa Received Received
  P-116 Characteristics and healthcare resource utilisation (HRU) of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) on enzalutamide (ENZ) or abiraterone acetate (AA) in England: PROCCO study Anna George Received Received
  P-117 Retrospective Study to Describe Characteristics and Treatment Patterns of Patients with Metastatic Castration-resistant Prostates Cancer Sahin Bahadir Received Received
  P-118 Real-world European study of treatment (tx) patterns in men with metastatic castration-resistant prostate cancer (mCRPC) Melissa Kirker Received Received
  P-128 The influence of the prostate radiotherapy dose in the prediction of complete response in synchronous oligometastatic prostate cancer patients Milo Gruji&263; Received Received
  P-129 Real-world data analysis of treatment outcomes for patients with metastatic hormone-sensitive prostate cancer: development of a survival prediction model. Results from the European network of excellence for big data in prostate cancer (PIONEER) Juan Gomez Rivas Received Received
  P-132 Reliability and efficiency of the CAPRI-3 metastatic prostate cancer registry powered by artificial intelligence Dianne Bosch Received Received
  P-133 Second line PSMA-targeted salvage treatment in patients with mi N1/M1a-b oligorecurrent PCa Martina Monti Received Received
  P-135 Homologous recombination repair mutation (HRRm) testing patterns among men with metastatic castration-resistant prostate cancer (mCRPC): Results from a real-world (rw) study in Europe Melissa Kirker Received Received
  P-139 Real-world (rw) homologous recombination repair (HRR) mutation testing patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in five European countries Melissa Kirker Received Received
  P-140 Patient-reported pain in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) enzalutamide (ENZA) vs placebo (PBO) ENZA: Results from a phase 3 (TALAPRO-2) study Saif Shaman Received Received
  P-144 COmplete ReSponse After systemic Immunotherapy /- Resection of residual disease in advanced ccRCC : the CORSAIR study Philippe Boudier Received Received
  P-155 Factors affecting acute kidney injury and subsequent renal function recovery after robot-assisted partial nephrectomy for clinical T1a renal masses Toshikazu Takeda Received Received
  P-156 Zanzalintinib (XL092) and nivolumab in nonclear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study (NCT05678673) Kim Nguyen Received Received
  P-160 Clinical characterisation, prognosis and assessment of predictive score for response to treatment of metastatic renal cells carcinoma with rhabdoid component Louis Vallois Received Received
  P-166 Real-world outcomes of cabozantinib treatment after first-line checkpoint inhibitor-based combination therapy for patients with advanced renal cell carcinoma: CARINA study results Lauren Reed Received Received
  P-168 Nivolumab as a treatment for metastatic renal cancer in second and successive lines. Experience at our hospital. María Luisa Garrido Onecha Received Received
  P-172 Perioperative and long-term oncological outcomes after local tumor ablation for complex (PADUA Score =10) cT1a renal tumors: a multicenter analysis Martina Monti Received Received
  P-174 The efficacy and safety of cone beam computed tomography for percutaneous renal cell carcinoma cryoablation: A single-center long-term follow-up study Matthijs Duijn Received Received
  P-178 Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential ion for adjuvant therapy Panagiotis Vlachostergios Received Received
  P-181 Proposal and internal validation of a nomogram for the prediction of local recurrence-free survival after percutaneous ablation for ct1 renal masses Sara Tamburini Received Received
  P-184 Monitoring of pulmonary function by diffusing capacity of lung for carbon monoxide(DLCO) during BEP therapy for testicular cancer Takeshi Kishida Received Received
  P-186 Overall Response rate with baby-BOP induction chemotherapy in patients with poor-risk, metastatic germ-cell tumors patients: A Retrospective Study in a Mexican hospital. Miriam Alejandra Nájar Rodríguez Received Received
  P-211 Endoscopic ablation of UTUC in solitary kidney patients Evangelia Papadimitriou Received Received
  P-212 Oncological outcomes of chemohyperthermia with HIVEC for BCG-unresponsive non-muscle invasive bladder cancer : results from a multicenter national database Géraldine Pignot Received Received
  P-214 C-reactive protein is a prognostic factor after pembrolizumab for metastatic upper urothelial carcinoma Hirotaka Nagasaka Received Received
  P-216 Neutrophil-to-eosinophil ratio (NER) predicts the efficacy of avelumab in patients with advanced Urothelial Carcinoma (aUC) enrolled in the MALVA study (Meet-URO 25) ELISABETTA GAMBALE Received Received
  P-219 Evaluation of the use of postoperative single-shot instillation chemotherapy after TURBT and reasons for not administering it Michal Fedorko Received Received
  P-224 Pembrolizumab Versus Atezolizumab in The Treatment of Advanced Urothelial Cancer: A Single Institution Experience Nafie Makady Received Received
  P-225 A real word study of avelumab first-line maintenance in advanced urothelial carcinoma Helena Guedes Received Received
  P-226 Delay of radical cystectomy in patients treated with neoadjuvant chemotherapy is associated with worse oncological outcomes Sieb Nuijens Received Received
  P-228 Neoadjuvant versus adjuvant chemotherapy in muscle-invasive bladder cancer: The RealBLADDER study. Results on behalf of the GOIRC ELISABETTA GAMBALE Received Received
  P-241 Atezolizumab as treatment of urothelial carcinoma in second line of metastatic disease. Experience in our institution. Laura Lopez Received Received
  P-244 COVID-19 pandemic and non-muscle-invasive bladder cancer: impact on follow-up and disease recurrence Frederico Portugal Gaspar Received Received
  P-251 Inhibitory coreceptors in variant histologies of bladder cancer the next chapter in urooncology? Severin Rodler Received Received
  P-254 Prognostic factors for urachal carcinoma Atsuto Suzuki Received Received
  P-256 Prognostic relevance of Platelet-to-Lymphocyte Ratio in patients with Muscle-Invasive Bladder Cancer Patients: real world data from a retrospective multicenter analysis Giovanna Pecoraro Received Received
  P-264 The prognostic value of pre-neoadjuvant chemotherapy prognostic nutritional index, systemic inflammatory response index and neutrophil-to-lymphocyte ratio in muscle invasive bladder cancer Maria Joao Ramos Received Received
  P-266 Gender Influence on Efficacy and Immune-Related Adverse Events of Immune Checkpoint Inhibitors in Metastatic Urothelial Cancer Patients Can Aydogdu Received Received
  P-268 Health-related Quality of Life Outcomes in patients with Muscle Invasive Bladder Cancer after treatment: Results of a Large, Population-based, Prospective Cohort Siberyn Nuijens Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
13:38
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

15th European Multidisciplinary Congress on Urological Cancers (EMUC23)

 

02-05 November 2023 Marseille
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 02/11/2023 TO 02/11/2024
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
 
Logo Cert